This is the first randomized clinical trial of transcatheter aortic valve implantation (TAVI). It showed that 1-year outcomes are dramatically improved among patients who are not candidates for ...

P atients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

This procedure is known as Transcatheter Aortic Valve Replacement (TAVR) or Transcatheter Aortic Valve Implantation (TAVI). Since then, many studies have been conducted across all risk categories ...

Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence ...

self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling stroke at five years compared with those whose valves were replaced through standard ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...